Abstract 891MO
Background
FL is biologically and clinically heterogeneous with wide variations in outcomes. Progression of disease within 24 months after treatment (POD24) predicts overall survival (OS) in patients (pts) treated with rituximab-based therapy. Pts with POD24 have a < 50% long-term survival. Identifying predictors of POD24 at outset is an area of unmet need. Total metabolic tumor volume (TMTV) is an independent predictor of outcomes in FL. However, TMTV calculations are not routinely available, unlike SUVmax. Thus, we aimed at determining the correlation of baseline SUVmax with POD24 in FL.
Methods
We performed a retrospective chart review of pts with newly diagnosed FL from January 2011-January 2019. Comparison of PFS was done with log-rank test and multivariate analysis was conducted with Cox regression.
Results
100 pts with median age 60 years (29-86 years) were included. Baseline characteristics are mentioned in the attached figure. 21% of pts relapsed within 24 months (POD24) however median OS was unable to be calculated due to insufficient OS events. Baseline PET-CT analysis showed median SUV max value of 8.55 (0-38.9). No difference in correlation was noted between baseline SUVmax and initial laboratory data collected (ANC, ALC, Hgb, Plt, LDH, albumin, and globulin). Median SUV max for POD24 pts was higher at 9.19 vs 7.40 for non-POD24 however, comparison of SUVmax by POD24 status showed no statistically significant difference between the two groups (p=0.95). T-test also failed to note a difference between baseline laboratory variables and PET-CT determinates (number of nodal and extranodal sites) between POD24 and non-POD24 pts.
Conclusions
In our analysis, baseline SUVmax did not predict POD24 nor were there significant differences in the comparison of clinical variables between the two POD24 groups. Gene-expression profiling (GEP) scores have been developed to predict PFS in FL and high-risk signatures have been found to react differently to different chemotherapy backbones. Future research efforts should focus on increasing the feasibility and adoption of GEP in clinical practice, defining molecular subtypes of FL prior to treatment, and assigning therapy on the basis of those results.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
886MO - Health-related quality of life (HRQoL) from KEYNOTE-204: A phase III, randomized, open-label study of pembrolizumab (pembro) vs brentuximab vedotin (BV) in relapsed or refractory classical Hodgkin lymphoma (R/R cHL)
Presenter: Pier Luigi Zinzani
Session: Mini Oral - Haematological malignancies
Resources:
Abstract
Slides
Webcast
887MO - Real-world treatment management of patients with advanced-stage classic Hodgkin lymphoma receiving front line therapy
Presenter: Abraham Avigdor
Session: Mini Oral - Haematological malignancies
Resources:
Abstract
Slides
Webcast
888MO - Effectiveness of brentuximab vedotin in relapsed/refractory classic Hodgkin lymphoma: A systematic review and meta-analysis
Presenter: Bastian von Tresckow
Session: Mini Oral - Haematological malignancies
Resources:
Abstract
Slides
Webcast
889MO - Long-term follow-up of patients with nodular lymphocyte predominant Hodgkin lymphoma: A report from the Spanish Lymphoma Oncology Group
Presenter: Beatriz Nunez Garcia
Session: Mini Oral - Haematological malignancies
Resources:
Abstract
Slides
Webcast
LBA37 - A blinded, randomized, parallel group, comparative investigation of a novel device (Cooral) for cryoprevention of oral mucositis
Presenter: Java Walladbegi
Session: Mini Oral - Haematological malignancies
Resources:
Abstract
Slides
Webcast
890MO - Phase I Alexander study of AUTO3, the first CD19/22 dual targeting CAR.T cell, with pembrolizumab in patients with relapsed/refractory (r/r) DLBCL
Presenter: Eleni Tholouli
Session: Mini Oral - Haematological malignancies
Resources:
Abstract
Slides
Webcast
892MO - High-dose chemotherapy with autologous hematopoietic stem cell transplantation in patients with HIV-related lymphoma
Presenter: Marina Popova
Session: Mini Oral - Haematological malignancies
Resources:
Abstract
Slides
Webcast
893MO - An open-label, single-center, phase II, single-arm trial of camrelizumab combined with apatinib in patients with relapsed or refractory peripheral T-cell lymphoma
Presenter: Yan Xie
Session: Mini Oral - Haematological malignancies
Resources:
Abstract
Slides
Webcast
Open & welcome
Presenter: Andrew Davies
Session: Mini Oral - Haematological malignancies
Resources:
Slides
Webcast
Invited Discussant 886MO, 887MO, 888MO and 889MO
Presenter: Stefan Balabanov
Session: Mini Oral - Haematological malignancies
Resources:
Slides
Webcast